首页 > 最新文献

Critical Reviews in Therapeutic Drug Carrier Systems最新文献

英文 中文
Cyclodextrin-Based Arsenal for Anti-Cancer Treatments. 基于环糊精的抗癌药物库。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038398
Hitesh Chopra, Ravinder Verma, Sakshi Kaushik, Jatin Parashar, Kumud Madan, Afsareen Bano, Rashmi Bhardwaj, Parijat Pandey, Beena Kumari, Deepika Purohit, Manish Kumar, Saurabh Bhatia, Md Habibur Rahman, Vineet Mittal, Inderbir Singh, Deepak Kaushik

Anti-cancer drugs are mostly limited in their use due to poor physicochemical and biopharmaceutical properties. Their lower solubility is the most common hurdle limiting their use upto their potential. In the recent years, the cyclodextrin (CD) complexation have emerged as existing approach to overcome the problem of poor solubility. CD-based nano-technological approaches are safe, stable and showed well in vivo tolerance and greater payload for encapsulation of hydrophobic drugs for the targeted delivery. They are generally chosen due to their ability to get self-assembled to form liposomes, nanoparticles, micelles and nano-sponges etc. This review paper describes a birds-eye view of the various CD-based nano-technological approaches applied for the delivery of anti-cancer moieties to the desired target such as CD based liposomes, niosomes, niosoponges, micelles, nanoparticles, monoclonal antibody, magnetic nanoparticles, small interfering RNA, nanorods, miscellaneous formulation of anti-cancer drugs containing CD. Moreover, the author also summarizes the various shortcomings of such a system and their way ahead.

抗癌药物由于其物理化学和生物制药性能较差,大多限制了其使用。它们较低的溶解度是限制它们发挥其潜力的最常见障碍。近年来,环糊精(CD)络合已成为克服溶解度差问题的一种可行方法。基于cd的纳米技术方法安全、稳定,具有良好的体内耐受性和更大的负载,可用于包封疏水药物进行靶向递送。通常选择它们是因为它们具有自组装形成脂质体、纳米颗粒、胶束和纳米海绵等的能力。本文概述了各种基于CD的纳米技术方法,如基于CD的脂质体、乳质体、乳球、胶束、纳米颗粒、单克隆抗体、磁性纳米颗粒、小干扰RNA、纳米棒、含CD的抗癌药物的各种配方,并总结了这种系统的各种缺点和未来的发展方向。
{"title":"Cyclodextrin-Based Arsenal for Anti-Cancer Treatments.","authors":"Hitesh Chopra,&nbsp;Ravinder Verma,&nbsp;Sakshi Kaushik,&nbsp;Jatin Parashar,&nbsp;Kumud Madan,&nbsp;Afsareen Bano,&nbsp;Rashmi Bhardwaj,&nbsp;Parijat Pandey,&nbsp;Beena Kumari,&nbsp;Deepika Purohit,&nbsp;Manish Kumar,&nbsp;Saurabh Bhatia,&nbsp;Md Habibur Rahman,&nbsp;Vineet Mittal,&nbsp;Inderbir Singh,&nbsp;Deepak Kaushik","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038398","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038398","url":null,"abstract":"<p><p>Anti-cancer drugs are mostly limited in their use due to poor physicochemical and biopharmaceutical properties. Their lower solubility is the most common hurdle limiting their use upto their potential. In the recent years, the cyclodextrin (CD) complexation have emerged as existing approach to overcome the problem of poor solubility. CD-based nano-technological approaches are safe, stable and showed well in vivo tolerance and greater payload for encapsulation of hydrophobic drugs for the targeted delivery. They are generally chosen due to their ability to get self-assembled to form liposomes, nanoparticles, micelles and nano-sponges etc. This review paper describes a birds-eye view of the various CD-based nano-technological approaches applied for the delivery of anti-cancer moieties to the desired target such as CD based liposomes, niosomes, niosoponges, micelles, nanoparticles, monoclonal antibody, magnetic nanoparticles, small interfering RNA, nanorods, miscellaneous formulation of anti-cancer drugs containing CD. Moreover, the author also summarizes the various shortcomings of such a system and their way ahead.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 2","pages":"1-41"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems. 设计质量在纳米载体给药系统的处方和开发中的实施。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022042927
Sonal Mehrotra, A Salwa, Lalit Kumar

Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.

设计质量(QbD)最近吸引了研究人员将其应用于制药趋势的各个领域。通过克服传统的过程,QbD防止了由“猜测和上帝方法”引起的错误风险。这个框架通过暗示健全的科学和风险评估策略,培养了对产品和过程质量的深刻认识。QbD的优点导致了制药工业家的协作贡献,并满足了监管机构。此外,导致快速生产,节省时间和支出,巨大的多功能性,提供大量的知识,提高鲁棒性,更高的一致性,减少用户的困境,减少失败的确定性,减少药品开发中的批次间变化。在这个不断增长的连续生产世界中,监管机构,如美国食品和药物管理局和国际协调会议推荐Q8到Q14指南,以获得所需的高质量产品。本文综述了QbD在纳米载体给药系统开发中的应用。此外,还记录了QbD在过程和分析方法开发技术中的应用。
{"title":"Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems.","authors":"Sonal Mehrotra,&nbsp;A Salwa,&nbsp;Lalit Kumar","doi":"10.1615/CritRevTherDrugCarrierSyst.2022042927","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022042927","url":null,"abstract":"<p><p>Quality by design (QbD) has recently fascinated researchers for utilizing it in various arenas of pharma trends. By overcoming the conventional process, QbD prevents the risk of errors caused by the 'guess and by god approach'. This framework fosters profound knowledge of product and process quality by implying sound science and risk assessment strategies. The virtue of QbD leads to the collaborative contribution to pharmaceutical industrialists and satisfies the regulatory bodies. Additionally, leading to rapid production, saves time and expenditure, tremendous versatility, provides immense knowledge, improves robustness, higher consistency, reduces user's dilemma, decreases certainty of failure, declining inter-batch variation in pharmaceutical development. In this ever-increasing continuous production world, regulatory organizations such as the U.S. Food & Drug Administration and the International Conference on Harmonization recommend Q8 to Q14 guidelines in order to obtain the desired quality product. This review extensively discusses on various approaches of QbD for the pharmaceutical development of nano-carrier drug delivery systems. Additionally, QbD's applications in process and analytical method development techniques are documented.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"40 3","pages":"1-46"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9228613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting pathways and integrated approaches to treat Rheumatoid Arthritis 治疗类风湿关节炎的靶向途径和综合方法
4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2023044719
Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh
Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.
类风湿性关节炎(RA)是一种慢性对称性全身性疾病,不仅会影响关节,还会影响心脏、肺、肾和肝脏等其他器官。大约有0.5% -1%的人口受到类风湿关节炎的影响。RA的发病机制尚不清楚,因此其适当的治疗是一个挑战。此外,据报道,多种因素影响其进展,如遗传因素、环境因素、免疫因素和氧化因素。可用于治疗类风湿性关节炎的治疗方法包括非甾体抗炎药、dmard、酶、激素和基因治疗。但它们大多只是缓解症状,而没有治疗疾病的核心。这使得探索和达到治疗和长期缓解类风湿性关节炎的分子靶点势在必行。在此,我们试图提供广泛覆盖的RA治疗新靶点,如影响疾病进展及其严重程度的信号通路、蛋白质和受体。对这些靶点进行精确修饰,如抑制notch信号通路、SIRT - 3蛋白、鞘氨醇-1-磷酸受体,刺激神经元信号,特别是传出迷走神经和SIRT -1蛋白,可能会提供长期的缓解,并可能减少慢性。为了靶向或改变新的分子和信号通路,需要一种特定的递送系统,如脂质体、纳米颗粒和胶束等。本文就治疗类风湿性关节炎的新靶点和给药系统进行了综述。
{"title":"Targeting pathways and integrated approaches to treat Rheumatoid Arthritis","authors":"Shradha Devi Dwivedi, Krishna Yadav, Anita Bhoi, Keshav Kant Sahu, Neelam Sangwan, Deependra Singh, Manju Singh","doi":"10.1615/critrevtherdrugcarriersyst.2023044719","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2023044719","url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5% -1% of the total population affected by rheumatoid arthritis. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long term relief from rheumatoid arthritis. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signalling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signalling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. In these review paper we have discuss about novel targets and delivery system for treating RA.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135612283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-Assembly Polymeric Nano Micelles for the Futuristic Treatment of Skin Cancer and Phototoxicity: Therapeutic and Clinical Advancement. 自组装聚合物纳米胶束用于皮肤癌和光毒性的未来治疗:治疗和临床进展。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2021035589
N. Mehan, Manish Kumar, S. Bhatt, R. Shankar, B. Kumari, R. Pahwa, Deepak Kaushik
In the last few years, the polymeric micelles played a major role as a drug carrier in nano-sized drug delivery system. The polymeric micelles are designed from synthetic block co-polymers and graft copolymers. In the mixed micelles, the bilayer lipid membrane and surfactants are used. Both micelles are in nano-sized and used to enhance the drug delivery to treat different diseases. In this review, we will discuss some examples from the literature included demonstrating the polymeric micelles used as drug-carriers in skin cancer treatment by using different drugs. We also summarized mixed micelles, polymeric micelles in skin drug delivery, various polymers, and techniques of polymeric micelles. These micelles may improve delivery of drug in the skin's targeted sites in specific and dermatological diseases like skin cancer, acne, and fungal infection. In the comparison of surfactant micelles, the polymeric micelles are more stable. Polymeric micelles act as a colloidal carrier for incorporating poorly water-soluble and amphiphilic drugs.
近年来,高分子胶束作为药物载体在纳米给药系统中发挥了重要作用。聚合物胶束是由合成的嵌段共聚物和接枝共聚物设计而成的。在混合胶束中,使用双层脂质膜和表面活性剂。这两种胶束都是纳米级的,用于增强药物传递,以治疗不同的疾病。在这篇综述中,我们将讨论一些文献中的例子,包括通过不同的药物来证明聚合物胶束作为药物载体在皮肤癌治疗中的应用。综述了混合胶束、聚合物胶束在皮肤给药中的应用、各种聚合物和聚合物胶束技术。这些胶束可以改善特定皮肤疾病(如皮肤癌、痤疮和真菌感染)的靶向部位的药物递送。与表面活性剂胶束相比,聚合物胶束更稳定。聚合物胶束作为一种胶体载体,将水溶性差的两亲性药物结合在一起。
{"title":"Self-Assembly Polymeric Nano Micelles for the Futuristic Treatment of Skin Cancer and Phototoxicity: Therapeutic and Clinical Advancement.","authors":"N. Mehan, Manish Kumar, S. Bhatt, R. Shankar, B. Kumari, R. Pahwa, Deepak Kaushik","doi":"10.1615/critrevtherdrugcarriersyst.2021035589","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2021035589","url":null,"abstract":"In the last few years, the polymeric micelles played a major role as a drug carrier in nano-sized drug delivery system. The polymeric micelles are designed from synthetic block co-polymers and graft copolymers. In the mixed micelles, the bilayer lipid membrane and surfactants are used. Both micelles are in nano-sized and used to enhance the drug delivery to treat different diseases. In this review, we will discuss some examples from the literature included demonstrating the polymeric micelles used as drug-carriers in skin cancer treatment by using different drugs. We also summarized mixed micelles, polymeric micelles in skin drug delivery, various polymers, and techniques of polymeric micelles. These micelles may improve delivery of drug in the skin's targeted sites in specific and dermatological diseases like skin cancer, acne, and fungal infection. In the comparison of surfactant micelles, the polymeric micelles are more stable. Polymeric micelles act as a colloidal carrier for incorporating poorly water-soluble and amphiphilic drugs.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 2 1","pages":"79-95"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
A Critical Review on Floating Tablets as a Tool for Achieving Better Gastric Retention. 漂浮片剂作为改善胃潴留的重要工具。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2021038568
Anjali Rajora, Kalpana Nagpal

Most of the oral drug delivery systems demand better retention of drug in the gastrointestinal tract (GIT) for better bioavailability. One of the tools for better gastric retention of the drug is to administer it as a floating drug delivery system (FDDS) by reducing its density, compared to the gastric fluids. This system is helpful to overcome the problems associated with the conventional pharmaceutical dosage forms. The present work is an effort to systematically review the latest advancements in FDDS with a major spotlight on how these systems act to make the dosage form float in the gastric fluid for the slow release, better gastric retention, and improved bioavailability of the orally administered drug. As managing diseases through medicines is going in a new age in which innovative delivery system is being used as well as made accessible for remedial use. The excipients used for making such oral gastro-retention dosage forms (GRDF) to provide sustained release profile of drugs along with the work done so far by different scientists in the past two decades; the patents filed in this area; the evaluation methods for checking the quality of FDDS; and their applications are the major highlights of this work.

为了获得更好的生物利用度,大多数口服给药系统需要更好的药物在胃肠道(GIT)中的保留。与胃液相比,通过降低药物的密度,将其作为一种漂浮药物输送系统(FDDS)进行管理,是改善药物胃潴留的工具之一。该系统有助于克服与传统药物剂型相关的问题。本文系统地回顾了FDDS的最新进展,重点介绍了这些系统如何使剂型漂浮在胃液中,以减缓释放,改善胃潴留,提高口服给药药物的生物利用度。由于通过药物管理疾病正在进入一个新的时代,在这个时代,人们正在使用创新的给药系统,并使其可用于治疗。用于制造这种提供药物缓释的口服胃保留剂型(GRDF)的赋形剂,以及过去二十年来不同科学家所做的工作;在该领域申请的专利;FDDS质量检验的评价方法;它们的应用是本工作的主要亮点。
{"title":"A Critical Review on Floating Tablets as a Tool for Achieving Better Gastric Retention.","authors":"Anjali Rajora,&nbsp;Kalpana Nagpal","doi":"10.1615/CritRevTherDrugCarrierSyst.2021038568","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021038568","url":null,"abstract":"<p><p>Most of the oral drug delivery systems demand better retention of drug in the gastrointestinal tract (GIT) for better bioavailability. One of the tools for better gastric retention of the drug is to administer it as a floating drug delivery system (FDDS) by reducing its density, compared to the gastric fluids. This system is helpful to overcome the problems associated with the conventional pharmaceutical dosage forms. The present work is an effort to systematically review the latest advancements in FDDS with a major spotlight on how these systems act to make the dosage form float in the gastric fluid for the slow release, better gastric retention, and improved bioavailability of the orally administered drug. As managing diseases through medicines is going in a new age in which innovative delivery system is being used as well as made accessible for remedial use. The excipients used for making such oral gastro-retention dosage forms (GRDF) to provide sustained release profile of drugs along with the work done so far by different scientists in the past two decades; the patents filed in this area; the evaluation methods for checking the quality of FDDS; and their applications are the major highlights of this work.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 1","pages":"65-103"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39746606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Recent Progress in Self-Emulsifying Drug Delivery Systems: A Systematic Patent Review (2011-2020). 自乳化给药系统的最新进展:系统专利审查(2011-2020)。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2021038490
Pedro Sebastián Londoño Ruiz, M. Serafini, I. Alves, Diana Marcela Aragón Novoa
Self-emulsifying drug delivery systems (SEDDS) are lipid-based isotropic mixtures that enhance the bioavailability of poorly water-soluble drugs and reduce the possible side effects, offering a wide variety of treatments for several pathologies. The aim of this review is to discuss the state of the art of patents for this drug delivery system by studying recent patent applications (2011 to 2020). We performed a thorough screening using the European Patent Office's Espacenet database, from which 37 inventions were selected and fully studied. China had more patent applications, and the articles published about SEDDS exceeds both in number and technological advance the submitted inventions. Nevertheless, the patents presented herein are innovative to address known issues to traditional SEDDS, including storage and formulation stability, solid formulations, acute gastrointestinal toxicity from surfactants, and drug delivery through alternative routes of administration. This study also revealed that release behavior for SEDDS and associated pharmacokinetics were not completely disclosed by the inventors of the patents and that further studies are required.
自乳化给药系统(SEDDS)是一种基于脂质的各向同性混合物,可提高水溶性差药物的生物利用度,减少可能的副作用,为多种疾病提供多种治疗方法。本综述的目的是通过研究最近的专利申请(2011年至2020年)来讨论该药物输送系统的专利现状。我们使用欧洲专利局的Espacenet数据库进行了彻底的筛选,从中选择了37项发明并进行了充分的研究。中国有更多的专利申请,发表的关于SEDDS的文章在数量和技术进步上都超过了提交的发明。然而,本文提出的专利是创新的,解决了传统SEDDS的已知问题,包括储存和配方稳定性,固体配方,表面活性剂的急性胃肠道毒性,以及通过其他给药途径给药。本研究还发现,专利发明人未完全披露SEDDS的释放行为和相关药代动力学,需要进一步研究。
{"title":"Recent Progress in Self-Emulsifying Drug Delivery Systems: A Systematic Patent Review (2011-2020).","authors":"Pedro Sebastián Londoño Ruiz, M. Serafini, I. Alves, Diana Marcela Aragón Novoa","doi":"10.1615/critrevtherdrugcarriersyst.2021038490","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2021038490","url":null,"abstract":"Self-emulsifying drug delivery systems (SEDDS) are lipid-based isotropic mixtures that enhance the bioavailability of poorly water-soluble drugs and reduce the possible side effects, offering a wide variety of treatments for several pathologies. The aim of this review is to discuss the state of the art of patents for this drug delivery system by studying recent patent applications (2011 to 2020). We performed a thorough screening using the European Patent Office's Espacenet database, from which 37 inventions were selected and fully studied. China had more patent applications, and the articles published about SEDDS exceeds both in number and technological advance the submitted inventions. Nevertheless, the patents presented herein are innovative to address known issues to traditional SEDDS, including storage and formulation stability, solid formulations, acute gastrointestinal toxicity from surfactants, and drug delivery through alternative routes of administration. This study also revealed that release behavior for SEDDS and associated pharmacokinetics were not completely disclosed by the inventors of the patents and that further studies are required.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"49 1","pages":"1-77"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Immunomodulation and Anticancer Immunity: Reviewing the Potential of Probiotics and Their Delivery with Macromolecular Carriers. 免疫调节和抗癌免疫:益生菌的潜力及其与大分子载体的传递。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2021040045
S. Tiwari, M. Dwivedi, Sachin Rathod, P. Bahadur
Probiotics colonize in the gastrointestinal tract and regulate the homeostasis in healthy human hosts. These protect the host against putrefactive organisms and secrete soluble factors exhibiting important transductive roles. However, constitutive processes in human host are deregulated following dysbiosis caused during prolonged exposure to cytotoxic agents and pollutants. Apart from restoring the homeostasis, probiotic administration has shown to minimize carcinogenesis and post-surgery complications in cancer patients. Moreover, ability of microbial cells to colonize at tumor foci can be harnessed to deliver genes, therapeutic proteins and antibodies in a selective manner. In this review, we have discussed immunomodulatory roles of probiotics in context to cancer prevention. The article further proposes the use of dietary interventions for boosting anticancer immunity and as an alternative to detrimental chemotherapeutic agents. After summarizing clinical evidences on probiotic efficacy, formulation approaches have been described for effective delivery of the microorganisms. The literature shows that polysaccharide matrices can be employed to achieve the survivability of probiotics. Formulation approaches have been reviewed together with the risks associated with the migration of live microorganisms to systemic circulation and their ability of transmitting antibiotic resistance factors into human pathogens.
益生菌定植于胃肠道并调节健康人类宿主的体内平衡。它们保护宿主免受腐殖生物的侵害,并分泌具有重要转导作用的可溶性因子。然而,在长期暴露于细胞毒性物质和污染物引起的生态失调后,人类宿主的构成过程被解除调控。除了恢复体内平衡外,益生菌管理已被证明可以最大限度地减少癌症患者的致癌和术后并发症。此外,微生物细胞在肿瘤病灶上定植的能力可以被利用,以选择性的方式传递基因、治疗蛋白和抗体。在这篇综述中,我们讨论了益生菌在癌症预防中的免疫调节作用。本文进一步提出使用饮食干预来增强抗癌免疫,并作为有害化疗药物的替代方案。在总结了益生菌功效的临床证据后,描述了有效递送微生物的配方方法。文献表明,多糖基质可以实现益生菌的生存能力。对制剂方法以及活微生物向体循环迁移的风险及其向人类病原体传播抗生素耐药因子的能力进行了审查。
{"title":"Immunomodulation and Anticancer Immunity: Reviewing the Potential of Probiotics and Their Delivery with Macromolecular Carriers.","authors":"S. Tiwari, M. Dwivedi, Sachin Rathod, P. Bahadur","doi":"10.1615/critrevtherdrugcarriersyst.2021040045","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2021040045","url":null,"abstract":"Probiotics colonize in the gastrointestinal tract and regulate the homeostasis in healthy human hosts. These protect the host against putrefactive organisms and secrete soluble factors exhibiting important transductive roles. However, constitutive processes in human host are deregulated following dysbiosis caused during prolonged exposure to cytotoxic agents and pollutants. Apart from restoring the homeostasis, probiotic administration has shown to minimize carcinogenesis and post-surgery complications in cancer patients. Moreover, ability of microbial cells to colonize at tumor foci can be harnessed to deliver genes, therapeutic proteins and antibodies in a selective manner. In this review, we have discussed immunomodulatory roles of probiotics in context to cancer prevention. The article further proposes the use of dietary interventions for boosting anticancer immunity and as an alternative to detrimental chemotherapeutic agents. After summarizing clinical evidences on probiotic efficacy, formulation approaches have been described for effective delivery of the microorganisms. The literature shows that polysaccharide matrices can be employed to achieve the survivability of probiotics. Formulation approaches have been reviewed together with the risks associated with the migration of live microorganisms to systemic circulation and their ability of transmitting antibiotic resistance factors into human pathogens.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 2 1","pages":"97-120"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cyclodextrin-Based Supramolecular Ternary Complexes: Emerging Role of Ternary Agents on Drug Solubility, Stability, and Bioavailability. 基于环糊精的超分子三元配合物:三元制剂在药物溶解度、稳定性和生物利用度方面的新作用。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2022038870
Pooja Suvarna, Pinal Chaudhari, Shaila A Lewis

The aqueous solubility of active drug moiety plays a crucial role in the development of an efficacious formulation. The poor aqueous solubility of BCS class II and IV drugs is manifested as poor bioavailability. Preparation of cyclodextrin inclusion complex to improve the solubility, stability, and bioavailability is a well-established technique. The latest trend in cyclodextrin research is focused on ternary complexes wherein an auxiliary agent such as water-soluble polymers, organic ions, metals, or amino acids is incorporated in the inclusion complex. The cyclodextrin-based supramolecular ternary complex offers significant advantages over binary complex specifically for oral drug delivery. Compared with the binary complex, the ternary complex exhibits better complexation efficiency and stability constant. Moreover, the ternary complex has a major advantage of reducing the concentration of cyclodextrin required to achieve maximum solubility and stability. Lately, in silico molecular modeling has gained tremendous attention as a preliminary tool to evaluate the cyclodextrin-based ternary or binary complex which has been discussed. This review gives an insight into various ternary agents explored worldwide, significant observations, safety, and clinical studies carried out on ternary cyclodextrin complexes.

活性药物部分的水溶性在有效制剂的开发中起着至关重要的作用。BCS II类和IV类药物水溶性差,表现为生物利用度差。制备环糊精包合物以提高溶解度、稳定性和生物利用度是一项成熟的技术。环糊精研究的最新趋势集中在三元配合物上,其中在包合物中加入助剂,如水溶性聚合物、有机离子、金属或氨基酸。以环糊精为基础的超分子三元配合物与二元配合物相比,具有明显的口服给药优势。与二元配合物相比,三元配合物具有更好的络合效率和稳定常数。此外,三元配合物的主要优点是降低了达到最大溶解度和稳定性所需的环糊精浓度。近年来,硅分子模拟作为评价环糊精基三元或二元配合物的初步工具受到了广泛的关注。本文综述了世界范围内开发的各种三元药物、重要观察结果、安全性和对三元环糊精配合物的临床研究。
{"title":"Cyclodextrin-Based Supramolecular Ternary Complexes: Emerging Role of Ternary Agents on Drug Solubility, Stability, and Bioavailability.","authors":"Pooja Suvarna,&nbsp;Pinal Chaudhari,&nbsp;Shaila A Lewis","doi":"10.1615/CritRevTherDrugCarrierSyst.2022038870","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2022038870","url":null,"abstract":"<p><p>The aqueous solubility of active drug moiety plays a crucial role in the development of an efficacious formulation. The poor aqueous solubility of BCS class II and IV drugs is manifested as poor bioavailability. Preparation of cyclodextrin inclusion complex to improve the solubility, stability, and bioavailability is a well-established technique. The latest trend in cyclodextrin research is focused on ternary complexes wherein an auxiliary agent such as water-soluble polymers, organic ions, metals, or amino acids is incorporated in the inclusion complex. The cyclodextrin-based supramolecular ternary complex offers significant advantages over binary complex specifically for oral drug delivery. Compared with the binary complex, the ternary complex exhibits better complexation efficiency and stability constant. Moreover, the ternary complex has a major advantage of reducing the concentration of cyclodextrin required to achieve maximum solubility and stability. Lately, in silico molecular modeling has gained tremendous attention as a preliminary tool to evaluate the cyclodextrin-based ternary or binary complex which has been discussed. This review gives an insight into various ternary agents explored worldwide, significant observations, safety, and clinical studies carried out on ternary cyclodextrin complexes.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 5","pages":"1-50"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40716835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Crafting Immunological Response Using Particulate Vaccines. 利用颗粒疫苗制造免疫反应。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/critrevtherdrugcarriersyst.2022040656
Amit Bansal, Bernadette D’Souza, D. Kapoor, P. Singh, Gretchen Starr, Kiran Muppireddy
To achieve optimal immunogenicity, particulates present a promising vehicle for antigen delivery and have the potential to skew immune response. Particulate vaccine offers several advantages including targeting of antigen to sentinel cells, protection from degradation, sustained release, and itself acts an adjuvant mimics viral structure. Adjuvant presence is vital in overcoming the poor immunogenicity of vaccines, e.g., subunit vaccines. Adjuvants have antigen dose sparing potential and provide danger signals to alert the immune system. Various particulate carriers received attention in the delivery of vaccine antigens such as virus-like particles, liposomes, immunostimulating complexes, and polymeric particles. This review also discussed the properties of particles such as size, shape, and rigidity affecting the immunological outcome. It further highlights the cellular uptake of the particulate vaccine, antigen processing, and its presentation by antigen-presenting cells. For mass vaccination, especially in countries lacking resources, effect of storage temperature condition on stability of vaccine is pivotal. The current COVID-19 pandemic is not showing any signs of abatement and role of nanocarriers are highly relevant in SARS-CoV-2 pandemic as an effective immunization strategy. Eradication of pandemic demands the rapid evaluation of multiple approaches that can provides successful vaccination platform, enabling scalability and global distribution.
为了获得最佳的免疫原性,颗粒呈现出一种有希望的抗原递送载体,并有可能扭曲免疫反应。颗粒疫苗具有几个优点,包括抗原靶向前哨细胞,防止降解,持续释放,并且本身作为佐剂模拟病毒结构。佐剂的存在对于克服疫苗(如亚单位疫苗)免疫原性差的问题至关重要。佐剂具有抗原剂量节约潜力,并提供危险信号提醒免疫系统。各种颗粒载体在疫苗抗原的递送中受到关注,如病毒样颗粒、脂质体、免疫刺激复合物和聚合物颗粒。本文还讨论了影响免疫结果的颗粒的大小、形状和硬度等特性。它进一步强调了颗粒疫苗的细胞摄取、抗原加工以及抗原呈递细胞的呈递。对于大规模疫苗接种,特别是在缺乏疫苗资源的国家,储存温度条件对疫苗稳定性的影响至关重要。当前的COVID-19大流行没有任何缓解迹象,纳米载体作为一种有效的免疫策略在SARS-CoV-2大流行中发挥着高度相关的作用。根除大流行需要对多种方法进行快速评估,这些方法可以提供成功的疫苗接种平台,实现可扩展性和全球分布。
{"title":"Crafting Immunological Response Using Particulate Vaccines.","authors":"Amit Bansal, Bernadette D’Souza, D. Kapoor, P. Singh, Gretchen Starr, Kiran Muppireddy","doi":"10.1615/critrevtherdrugcarriersyst.2022040656","DOIUrl":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2022040656","url":null,"abstract":"To achieve optimal immunogenicity, particulates present a promising vehicle for antigen delivery and have the potential to skew immune response. Particulate vaccine offers several advantages including targeting of antigen to sentinel cells, protection from degradation, sustained release, and itself acts an adjuvant mimics viral structure. Adjuvant presence is vital in overcoming the poor immunogenicity of vaccines, e.g., subunit vaccines. Adjuvants have antigen dose sparing potential and provide danger signals to alert the immune system. Various particulate carriers received attention in the delivery of vaccine antigens such as virus-like particles, liposomes, immunostimulating complexes, and polymeric particles. This review also discussed the properties of particles such as size, shape, and rigidity affecting the immunological outcome. It further highlights the cellular uptake of the particulate vaccine, antigen processing, and its presentation by antigen-presenting cells. For mass vaccination, especially in countries lacking resources, effect of storage temperature condition on stability of vaccine is pivotal. The current COVID-19 pandemic is not showing any signs of abatement and role of nanocarriers are highly relevant in SARS-CoV-2 pandemic as an effective immunization strategy. Eradication of pandemic demands the rapid evaluation of multiple approaches that can provides successful vaccination platform, enabling scalability and global distribution.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 4 1","pages":"49-82"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67437625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Challenges and Strategies for Topical and Transdermal Delivery of Bioactive Peptides. 生物活性肽局部和透皮递送的挑战和策略。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2022-01-01 DOI: 10.1615/CritRevTherDrugCarrierSyst.2021038141
Antonio Jiménez-Rodríguez, Daniela Guardado-Félix, Marilena Antunes-Ricardo

Bioactive peptides have gained the attention and interest of researchers and the industry for their therapeutic effects and high specificity, thus reducing the risks of side effects and making them an attractive alternatives in developing new biopharmaceuticals or cosmeceuticals. Nevertheless, their incorporation into formulations and administration presents challenges such as low stability under different storage conditions and gastrointestinal degradation after oral delivery. Likewise, the parenteral route is an invasive method that is painful and therefore reduces patient compliance. Topical delivery of bioactive peptides is a painless noninvasive alternative to reduce peptide degradation, exert local effects in the applied area, and improve patient compliance. In this review, we discuss the physicochemical properties of peptides and the mechanisms involved in their degradation. In addition, the most important aspects of skin structure and skin permeation routes, and the requirements for topical and transdermal drug delivery are also discussed in this article. Finally, nanocarrier development advances for the topical delivery of peptides (water-in-oil-in-water emulsions, microemulsions, nanoparticles, solid lipid nanoparticles, liposomes, niosomes, and microneedles) and other strategies, such as metal complexation, cell-penetrating peptides, and synthetic modification, are also reviewed. All these topics consider the perspective of their effect to improve skin permeability to peptides and their stability over time during storage.

生物活性肽因其具有良好的治疗效果和高特异性,降低了副作用的风险,成为开发新型生物制药或药妆品的一个有吸引力的替代方案,已引起研究人员和业界的关注和兴趣。然而,将其纳入制剂和给药面临挑战,如在不同储存条件下的低稳定性和口服给药后的胃肠道降解。同样,肠外途径是一种侵入性方法,是痛苦的,因此降低了患者的依从性。生物活性肽的局部递送是一种无痛、无创的替代方法,可以减少肽的降解,在应用区域发挥局部作用,提高患者的依从性。在这篇综述中,我们讨论了多肽的物理化学性质及其降解机制。此外,本文还讨论了最重要的皮肤结构和皮肤渗透途径,以及局部和透皮给药的要求。最后,综述了用于局部递送多肽的纳米载体的发展进展(水包油乳液、微乳液、纳米颗粒、固体脂质纳米颗粒、脂质体、乳质体和微针)以及其他策略,如金属络合、细胞穿透肽和合成修饰。所有这些主题都考虑了它们对改善皮肤对肽的渗透性及其在储存期间的稳定性的影响。
{"title":"Challenges and Strategies for Topical and Transdermal Delivery of Bioactive Peptides.","authors":"Antonio Jiménez-Rodríguez,&nbsp;Daniela Guardado-Félix,&nbsp;Marilena Antunes-Ricardo","doi":"10.1615/CritRevTherDrugCarrierSyst.2021038141","DOIUrl":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2021038141","url":null,"abstract":"<p><p>Bioactive peptides have gained the attention and interest of researchers and the industry for their therapeutic effects and high specificity, thus reducing the risks of side effects and making them an attractive alternatives in developing new biopharmaceuticals or cosmeceuticals. Nevertheless, their incorporation into formulations and administration presents challenges such as low stability under different storage conditions and gastrointestinal degradation after oral delivery. Likewise, the parenteral route is an invasive method that is painful and therefore reduces patient compliance. Topical delivery of bioactive peptides is a painless noninvasive alternative to reduce peptide degradation, exert local effects in the applied area, and improve patient compliance. In this review, we discuss the physicochemical properties of peptides and the mechanisms involved in their degradation. In addition, the most important aspects of skin structure and skin permeation routes, and the requirements for topical and transdermal drug delivery are also discussed in this article. Finally, nanocarrier development advances for the topical delivery of peptides (water-in-oil-in-water emulsions, microemulsions, nanoparticles, solid lipid nanoparticles, liposomes, niosomes, and microneedles) and other strategies, such as metal complexation, cell-penetrating peptides, and synthetic modification, are also reviewed. All these topics consider the perspective of their effect to improve skin permeability to peptides and their stability over time during storage.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"39 1","pages":"1-31"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39746604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Critical Reviews in Therapeutic Drug Carrier Systems
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1